A treatment company that sells longer-lasting add-ons or improved dosing methods for mitochondrial eye injections to retina clinics and drug developers.
Durability-Enhancing Therapies for Mitochondrial Ophthalmology
The Nature report (2026-08-24) of a first human mitochondrial eye injection showed the procedure appears safe but benefits fade quickly, so retina clinics and drug developers could use longer-lasting adjuncts or improved dosing protocols to make outcomes durable and more commercial. This creates a clear race to extend the effect and capture clinical uptake.
Projected Score
as a side gig ☆☆☆☆☆ (0/5)
no money or audience ☆☆☆☆☆ (0/5)
with both ★★☆☆☆ (2/5)
Want this one researched? Commission the full dossier for $15: we research and write it, and you read it first. Then you choose — pay more to keep it exclusive, or do nothing and it goes public on this site. The score above is our forecast for a dossier we haven’t written yet.
The news behind it
- Aug 24, 2026 Nature: Patient’s own mitochondria injected into eyes in attempt to restore vision
